The Medicines Company (MDCO) Seen as M&A Target Upon Clean Safety Data - Citi
Tweet Send to a Friend
Citi analyst Joel Beatty sees The Medicines Company (NASDAQ: MDCO) as a likely M&A target if Phase 3 data in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
